Brokerages Anticipate Bio-Path Holdings Inc (BPTH) to Announce -$0.20 Earnings Per Share

Wall Street brokerages expect that Bio-Path Holdings Inc (NASDAQ:BPTH) will post ($0.20) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Path’s earnings. Bio-Path posted earnings of ($0.10) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 100%. The firm is expected to issue its next earnings results on Wednesday, March 21st.

On average, analysts expect that Bio-Path will report full year earnings of ($0.80) per share for the current financial year. For the next financial year, analysts expect that the business will report earnings of ($0.90) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Bio-Path.

BPTH has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $15.00 price target (down from $45.00) on shares of Bio-Path in a research note on Monday, November 13th. dropped their price target on Bio-Path from $45.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Finally, ValuEngine upgraded Bio-Path from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $16.67.

Several hedge funds have recently bought and sold shares of BPTH. Renaissance Technologies LLC grew its stake in shares of Bio-Path by 64.9% in the fourth quarter. Renaissance Technologies LLC now owns 683,900 shares of the company’s stock valued at $138,000 after buying an additional 269,200 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Bio-Path in the fourth quarter valued at about $157,000. Sabby Management LLC grew its stake in shares of Bio-Path by 73.2% in the second quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock valued at $462,000 after buying an additional 503,488 shares in the last quarter. Finally, HighTower Advisors LLC grew its stake in shares of Bio-Path by 0.3% in the second quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after buying an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 9.31% of the company’s stock.

Shares of Bio-Path (BPTH) opened at $1.82 on Wednesday. The company has a market capitalization of $206.37, a PE ratio of -2.46 and a beta of 3.01. Bio-Path has a 12 month low of $1.55 and a 12 month high of $10.10.

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at

Bio-Path Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Get a free copy of the Zacks research report on Bio-Path (BPTH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.

Leave a Reply